Clinical Trial Update: Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India [Phase 4]

View source ↗

Summary

A Phase 4 trial update describing the safety of the 13-valent pneumococcal conjugate vaccine in children aged 6 to 17 years in India; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Prevention of Pneumococcal Infection

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Vaccines | Phase 4 | Status: COMPLETED | Results posted: 2020-04-21